Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Medline (MDLN) and Collegium Pharmaceutical (COLL)

Tipranks - Tipranks - Wed Mar 25, 2:48AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abivax SA Sponsored ADR (ABVX), Medline (MDLN) and Collegium Pharmaceutical (COLL) with bullish sentiments.

Claim 30% Off TipRanks Premium

Abivax SA Sponsored ADR (ABVX)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Abivax SA Sponsored ADR, with a price target of $148.00. The company’s shares closed last Monday at $115.42.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 25.7% and a 53.8% success rate. Darout covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Protagonist Therapeutics, and Iovance Biotherapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abivax SA Sponsored ADR with a $149.71 average price target, which is a 24.1% upside from current levels. In a report issued on March 15, Jefferies also initiated coverage with a Buy rating on the stock with a $160.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Medline (MDLN)

Barclays analyst Glen Santangelo maintained a Buy rating on Medline today and set a price target of $50.00. The company’s shares closed last Monday at $42.48.

According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 4.7% and a 50.2% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Amneal Pharmaceuticals, and Elanco Animal Health. ;'>

Currently, the analyst consensus on Medline is a Strong Buy with an average price target of $52.20, which is a 21.1% upside from current levels. In a report issued on March 12, TipRanks – PerPlexity also initiated coverage with a Buy rating on the stock with a $49.00 price target.

Collegium Pharmaceutical (COLL)

In a report released today, Jenna Davidner from Barclays maintained a Buy rating on Collegium Pharmaceutical, with a price target of $56.00. The company’s shares closed last Monday at $34.74.

According to TipRanks.com, Davidner is a 1-star analyst with an average return of -16.3% and a 0.0% success rate. Davidner covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Xeris Pharmaceuticals, and Alvotech. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $54.17 average price target, implying a 47.3% upside from current levels. In a report issued on March 19, Needham also maintained a Buy rating on the stock with a $56.00 price target.

Read More on ABVX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).